Compare ATS & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ATS | VCEL |
|---|---|---|
| Founded | 1978 | 1989 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.4B |
| IPO Year | 2007 | 1996 |
| Metric | ATS | VCEL |
|---|---|---|
| Price | $19.45 | $39.10 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $35.00 | ★ $57.75 |
| AVG Volume (30 Days) | 216.1K | ★ 430.3K |
| Earning Date | 05-27-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 60.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $276,259,000.00 |
| Revenue This Year | $17.99 | $19.40 |
| Revenue Next Year | $4.52 | $18.24 |
| P/E Ratio | $222.92 | ★ N/A |
| Revenue Growth | N/A | ★ 16.45 |
| 52 Week Low | $18.41 | $28.95 |
| 52 Week High | $35.82 | $49.32 |
| Indicator | ATS | VCEL |
|---|---|---|
| Relative Strength Index (RSI) | 37.27 | 29.87 |
| Support Level | $19.14 | $35.45 |
| Resistance Level | $20.11 | $39.48 |
| Average True Range (ATR) | 0.50 | 1.14 |
| MACD | 0.29 | -0.31 |
| Stochastic Oscillator | 53.24 | 1.46 |
ATS Corp is engaged in planning, designing, building, commissioning and servicing automated manufacturing systems - including automation products and test solutions - for a broadly diversified base of customers. The company focuses in five key markets: life sciences, food & beverage, transportation, consumer products and energy. The Company's operations are reported as one operating segment, Automation Systems, which plans, allocates resources, builds capabilities and implements practices on a world-wide basis. The company has presence in Canada, United States, Germany, Italy, Other Europe, and Other.
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.